Accepted for/Published in: JMIR Medical Informatics
Date Submitted: Jan 31, 2019
Open Peer Review Period: Feb 1, 2019 - Mar 29, 2019
Date Accepted: Aug 19, 2019
(closed for review but you can still tweet)
Impact on Readmission Reduction Among Heart Failure Patients Using Digital Health Monitoring: Feasibility and Adoption in a Real World Setting
ABSTRACT
Background:
Congestive heart failure (CHF) is a condition that affects approximately 6.5 million people in the U.S. with a mortality rate of around 30%. With the incidence rate expected to rise by 46% to exceed 8 million cases by 2030, projections estimate that total CHF costs will increase about to nearly $70 billion. Recently, the advent of remote monitoring technology has significantly broadened the scope of the physician’s reach in chronic disease management.
Objective:
The goal of this project was to see feasibility of using digital health monitoring in real world hospital setting, ascertain patient adoption and evaluate impact on 30-day readmission rate as primary outcome.
Methods:
A digital medicine software platform developed by Rx.Health, called RxUniverse, was used to prescribe HealthPROMISE and iHealth mobile apps to patients’ personal smartphones. Patients updated and recorded their CHF-related symptoms and quality of life measures daily on HealthPROMISE. Vital sign data, including blood pressure and weight, were collected through an ambulatory remote monitoring system that integrated the iHealth app and complementary consumer grade Bluetooth-connected smart devices (blood pressure cuff and digital scale). Physicians were notified of abnormal patient blood pressure and weight change readings and further action was left to the physician’s discretion. We used statistical analyses to determine risk factors associated with 30-day all-cause readmission.
Results:
Overall, the HeartHealth project included 60 patients admitted to Mount Sinai Hospital for CHF. There were six 30-day hospital readmissions (10% 30-day readmission rate), compared to the national readmission rates of around 25%. Single marital status (p = 0.064) and history of percutaneous coronary intervention (p = 0.075) were associated with readmission. Readmitted patients were also less likely to have been previously prescribed angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (p = 0.019). Notably, readmitted patients utilized the blood pressure and weight monitors less than non-readmitted patients, and patients aged less than 70 used the monitors more frequently on average than those over 70, though these trends did not reach statistical significance. The percentage of patients using the monitors at least once dropped steadily from 83% in the first week after discharge to 46% in the fourth week. Additionally, 88% of patients used the monitor at least 4 times and 62% at least 10 times, with some patients using the monitors multiple times per day.
Conclusions:
Given the increasing burden of CHF, there is a need for an effective and sustainable remote monitoring system for CHF patients following hospital discharge. We identified clinical and social factors as well as remote monitoring usage trends that identify targetable patient populations that could benefit most from integration of daily remote monitoring. In addition, we demonstrated that interventions driven by real-time vitals data may greatly aid in reducing hospital readmissions and costs while improving patient outcomes. Future studies should seek to measure population health-wide impact by expanding digital health remote monitoring enterprise-wide.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.